You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

36 search results for: itch

<b>Itch</b> in AD, PN, and CSU: Contributions of Type 2 Inflammation

expert video

Itch in AD, PN, and CSU: Contributions of Type 2 Inflammation

13 min

Dermatology

In this video from the ADVENT symposium from Fall Clinical 2023, join Dr. Raj Chovatiya as he explores the contribution of type 2 inflammation to itch in AD, PN, and CSU.

What Drives Chronic <b>Itch</b> and the <b>Itch</b>-Scratch Cycle in Atopic Dermatitis?

videoanimation

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

6 min

Dermatology

Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis

Role of Type 2 Inflammation in Prurigo Nodularis Part 2: <b>Itch</b> and Skin Lesions

expert video

Role of Type 2 Inflammation in Prurigo Nodularis Part 2: Itch and Skin Lesions

13 min

Dermatology

Dive deeper into the specific role of type 2 inflammation in neuroimmune dysregulation and dermal fibrosis that leads to itch and skin lesions seen in patients with prurigo nodularis with Dr. Raj Chovatiya in the second part of this discussion.

Disease-Specific Aspects of <b>Itch</b> in AD, PN, and CSU

expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

16 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

Unique Characteristics of <b>Itch</b> in AD, PN, and CSU – A Panel Discussion

expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

5 min

Dermatology

Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.

The Path to Nodules: Type 2 Inflammation at the Core of Chronic <b>Itch</b> and Fibrosis in Prurigo Nodularis

expert video

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

11 min

Type 2 Inflammation

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.

expert video

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria

45 min

Dermatology

Dr. Elmariah, Professor Metz, and Dr. Kim discuss the unique clinical presentations of PN and CSU and explore the shared and distinct pathophysiological underpinnings of itch and inflammation in both diseases, with a focus on the roles of type 2 cytokines at the neuroimmune axis In PN and CSU

expert video

Itch and Inflammation in Two Distinct Diseases: PN and CSU

20 min

Dermatology

Professor Metz discusses the unique clinical presentations of PN and CSU and explores the shared and distinct cellular underpinnings of itch and inflammation in both diseases

Role of Type 2 Inflammation in Skin Barrier Disruption and <b>Itch</b>

expert video

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

4 min

Dermatology

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD

videoanimation

The Pathophysiology of Prurigo Nodularis

5 min

Dermatology

An infographic exploring the pathophysiology of prurigo nodularis and the role of type 2 inflammation.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region